SAFETY DATA

EYLEA has a demonstrated safety
profile in Diabetic Retinopathy (DR)
and Diabetic Macular Edema (DME)1

DME (VISTA and VIVID: results in chart) and DR (PANORAMA: results below chart) Phase 3 Trials: Most Common Adverse Reactions (≥1%)1

Most common adverse reactions (AE) from EYLEA phase 3 trials: conjunctival hemorrhage, eye pain, cataract, vitreous floaters, corneal epithelium defect, intraocular pressure increase, ocular hyperemia, vitreous detachment, foreign body sensation in eyes, lacrimation increase, vision blurred, intraocular inflammation, injection-site pain, and eyelid edema

DR Phase 3 PANORAMA Trial

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information and Indications INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended for U.S. Doctors of Optometry.

References:

  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. August 2019.
  2. Wykoff C. Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study. Data presented at: Angiogenesis, Exudation and Degeneration Annual Meeting; February 8, 2020; Miami, FL.